TCGA-44-5643-01A-01R-1628-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 53
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.650
- MYC_TARGETS_V1+0.560
- OXIDATIVE_PHOSPHORYLATION+0.500
- E2F_TARGETS+0.470
- G2M_CHECKPOINT+0.450
- PI3K_AKT_MTOR_SIGNALING+0.340
- MITOTIC_SPINDLE+0.330
- MTORC1_SIGNALING+0.320
- UNFOLDED_PROTEIN_RESPONSE+0.280
- INTERFERON_ALPHA_RESPONSE+0.230
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.570
- ANGIOGENESIS-0.500
- COAGULATION-0.480
- MYOGENESIS-0.360
- TGF_BETA_SIGNALING-0.290
- APICAL_JUNCTION-0.280
- COMPLEMENT-0.280
- PANCREAS_BETA_CELLS-0.280
- KRAS_SIGNALING_UP-0.270
- HYPOXIA-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013511 | — | cohortSQ1 | 0.868 |
| 2 | TCGA-33-AASJ-01A-11R-A405-07 | — | cohortSQ2 | 0.868 |
| 3 | TCGA-58-A46K-01A-11R-A24H-07 | — | cohortSQ2 | 0.863 |
| 4 | TCGA-18-3419-01A-01R-0980-07 | — | cohortSQ1 | 0.853 |
| 5 | SRR6013515 | — | cohortA4 | 0.850 |
| 6 | TCGA-60-2719-01A-01R-0851-07 | — | cohortSQ1 | 0.850 |
| 7 | 504282dd-4fef-4f70-a709-6a545d00a263 | — | — | 0.843 |
| 8 | TCGA-BT-A20V-01A-11R-A14Y-07 | — | — | 0.842 |
| 9 | SRR8613729 | — | E | 0.842 |
| 10 | TCGA-58-A46M-01A-11R-A24H-07 | — | cohortSQ2 | 0.840 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.650 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.560 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.340 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.330 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.320 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.280 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.230 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.140 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.120 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.080 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.070 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.060 | Remibrutinib | — uncovered |